Get started
Author

Doreen Werchau

Observed name: Werchau, Doreen
ORCID: 0000-0002-6913-837X
Observed ORCID: 0000-0002-6913-837X
OpenAlex ID: A5025033564
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
2019 · Anne Månsson Kvarnhammar, Niina Veitonmäki, et al. · Journal for ImmunoTherapy of Cancer · 122
PDF
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
2022 · Karin Hägerbrand, Laura Varas, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
2021 · Adnan Deronic, Anneli Nilsson, et al. · Cancer Immunology Immunotherapy · 21
PDF
The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2022 · Michelle H. Nelson, Sara Fritzell, et al. · Molecular Cancer Therapeutics · 12
858 A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies
2020 · Peter Ellmark, Karin Hägerbrand, et al. · Journal for ImmunoTherapy of Cancer · 5
Abstract 2380: Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibody
2019 · Anna Dahlman, Michelle Nelson, et al. · Cancer Research · 3
751 Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb
2021 · Karin Hagerbrand, Mattias Levin, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Abstract 4155: Mitazalimab, a potent CD40 agonist in combination with chemotherapy redirects and activates tumor infiltrating myeloid cells
2022 · Karin Enell Smith, Mia Thagesson, et al. · Cancer Research · 1
Abstract 3623: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
2018 · Niina Veitonmäki, Mia Thagesson, et al. · Cancer Research · 1
Supplementary Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2025 · Michelle H. Nelson, Sara Fritzell, et al.
PDF
Supplementary Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2023 · Michelle H. Nelson, Sara Fritzell, et al.
PDF
Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2023 · Michelle H. Nelson, Sara Fritzell, et al.
Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2023 · Michelle H. Nelson, Sara Fritzell, et al.
Supplementary Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2023 · Michelle H. Nelson, Sara Fritzell, et al.
Abstract 2380: Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibody
2019 · Anna Dahlman, Michelle Nelson, et al. · Immunology
Abstract 695: The generation of a mono-selective CDK7 inhibitor.
2013 · Jan E. Eickhoff, Gunther Zischinsky, et al. · Cancer Research
Works count: 26
Citation count: 201
H-index: 5
I10-index: 4
Year
Topic
Type